

Glaucoma Surgery

Last Review Date: January 14, 2022

Number: MG.MM.SU.63eC2v2

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Aqueous Humor	Clear aqueous fluid, which fills the space between the lens and retina in the anterior chamber of the eye where it flows continuously in and out of the chamber nourishing nearby tissues. The fluid exits the chamber at the open angle, where the cornea and iris meet, and flows through a spongy meshwork drain.
Schlemm's Canal	Circular canal in the eye that drains aqueous humor from the anterior chamber of the eye into the anterior ciliary veins.
Intraocular pressure (IOP)	The pressure within the eye, which is maintained by a balance between aqueous fluid secretion and fluid outflow; in glaucoma, defects that interfere with aqueous humor outflow lead to a rise in intraocular pressure resulting in degenerative compromise of optic nerve function known as progressive optic nerve atrophy and vision loss.
Glaucoma	<p>A group of eye diseases characterized by increased IOP), which causes pathological changes in the optic disk and defects in the field of vision.</p> <ul style="list-style-type: none"> ▪ Open-angle glaucoma (OAG) — progressive form of glaucoma in which the drainage channel for the aqueous humor, composed of the attachment at the edge of the iris and the junction of the sclera and cornea, remains open, and in which serious vision-reduction occurs (advanced stages of the disease) due to tissue changes along the drainage channel. ▪ Primary open-angle glaucoma (POAG; aka chronic glaucoma) — most common type of glaucoma, which is associated with a build-up of aqueous fluid pressure within the eye that can lead to visual field loss and optic nerve damage (usually without any associated pain or discomfort). There is no abnormality in the anterior chamber angle; however, the aqueous fluid is unable to flow correctly. ▪ Secondary open-angle glaucoma (SOAG) —open angle glaucoma resulting from other medical conditions (e.g. pseudoexfoliative glaucoma, pigmentary glaucoma) or trauma. <p>The severity of glaucoma damage can be estimated using the following:</p> <ul style="list-style-type: none"> ▪ Mild — optic nerve abnormalities consistent with glaucoma and a normal visual field as tested with standard automated perimetry ▪ Moderate — optic nerve abnormalities consistent with glaucoma and visual field

	<p>abnormalities in one hemifield that are not within 5 degrees of fixation as tested with standard automated perimetry</p> <ul style="list-style-type: none"> ▪ Severe — optic nerve abnormalities consistent with glaucoma and visual field abnormalities in both hemifields and/or loss within 5 degrees of fixation in at least one hemifield as tested with standard automated perimetry
Hypotony	Abnormally low IOP of intraocular fluid; typically occurs as a complication of an underlying ocular disorder (such as uveitis or following a glaucoma surgery).
Aqueous shunts (Aka aqueous drainage devices or glaucoma drainage devices, setons, tube implants and tube shunts)	<p>Devices implanted into the eye to create an alternate pathway for aqueous humor drainage from the anterior or posterior eye-chamber to a space between the conjunctiva and the sclera where it is absorbed into the blood, thereby lowering IOP. These devices differ depending on explant surface areas, shape, plate thickness, the presence or absence of a valve and details of surgical installation. Generally, the risk of hypotony is reduced with aqueous shunts in comparison with trabeculectomy, but IOP outcomes are higher than after standard guarded filtration surgery.</p> <p>Other aqueous stents (e.g., microstents) are being developed as minimally penetrating methods to drain aqueous humor from the anterior chamber into Schlemm’s canal or the suprachoroidal space. These include the iStent® (Glaukos), which is a 1-mm long stent inserted into the end of Schlemm’s canal by an internal approach through the cornea and anterior chamber; and the third generation iStent supra®, which is designed for ab interno implantation into the suprachoroidal space. An advantage of ab interno shunts is that they may be inserted into the same incision and at the same time as cataract surgery. In addition, most devices do not preclude subsequent trabeculectomy if needed. It may also be possible to insert more than one shunt to achieve the desired IOP. (See Limitations/Exclusions)</p>
Trabeculectomy	A surgical filtration procedure in which a portion of the trabecular meshwork is surgically removed through a superficial flap of sclera to lower the IOP by creating an alternate pathway for the aqueous fluid to flow from the anterior chamber to a bleb created in the subconjunctival space; this is currently considered the gold standard treatment for glaucoma that is refractory to medical management.

Guideline

- A.** Laser trabeculoplasty, trabeculectomy* or FDA-approved aqueous drainage/shunt implants** are considered medically necessary for the treatment of refractory open-angle glaucoma when there is intolerance, contraindication or failure of topical/oral medication*** to control IOP. (Note: Goniotomy requests will be case-by-case reviewed)

* Antimetabolites such as 5-Fluorouracil (5-FU) may be considered medically necessary to inhibit wound healing to prevent the conjunctiva scarring down on to the sclera.

**Currently available FDA-approved implants include: Ahmed glaucoma implant, Baerveldt seton, Ex-PRESS mini glaucoma shunt, Glaucoma pressure regulator, Krupin-Denver valve implant, Molteno implant, Schocket shunt

*** First line examples include latanoprost or timolol; second line, brimonidine or dorzolamide, etc.

- B.** One iStent®, iStent inject or Hydrus® Microstent per eye is considered medically necessary when used in combination with cataract surgery for mild to moderate open-angle glaucoma, and a cataract, in adult members being treated with ocular hypotensive medication.
- C.** One XEN45 device per eye is covered for the management of refractory glaucoma,

defined as prior failure of filtering/cilioablative procedure and/or uncontrolled IOP (progressive damage and mean diurnal medicated IOP ≥ 20 mm Hg) on maximally tolerated medical therapy (i.e., ≥ 4 classes of topical IOP-lowering medications, or fewer in the case of tolerability or efficacy issues). XEN45 insertion must be performed by an ophthalmologist with experience with trabeculectomy and bleb management.

- D. Adjunctive use of anti-fibrotic agents (e.g., mitomycin C) is considered medically necessary for use with the Ex-PRESS mini glaucoma shunt

Limitations/Exclusions

The following treatments/procedures are not considered medically necessary due to insufficient evidence of therapeutic value:

1. Transciliary filtration for glaucoma or other indications (e.g., Fugo Blade transciliary filtration, Singh filtration)
2. Ab interno trabeculectomy (trabectome) (CPT 0621T, 0622T eff, 01/01/2021)
3. Beta radiation
4. Glaucoma drainage devices without FDA approval (e.g., Eyepass, DeepLight SOLX[®] Gold Shunt, which are inserted internally)
5. Adjunctive use of anti-fibrotic agents (e.g., mitomycin C) or systemic corticosteroids with shunt implants other than the Ex-Press mini
6. Drug-eluting implants inserted into the lacrimal canaliculus (including punctal dilation and implant removal when performed) for glaucoma or ocular hypertension (CPT 0356T, 0444T and 0445T)
7. Requests for trabeculoplasty for ocular hypertension will be reviewed on a case by case basis for members who have failed pharmaceutical management

Revision History

Sept. 11, 2020	Added a note pertaining to trabeculectomy regarding the prophylactic use of 5-Fluorouracil (5-FU)
Jul. 8, 2020	Added case-by-case review language for trabeculoplasty as a treatment for ocular hypertension
Jan. 10, 2020	Added iStent inject coverage and case-by-case language for goniotomy
Dec. 14, 2018	Added coverage for Hydrus
Sept. 14, 2018	Removed CyPass as a covered device due to Alcon recall Aug. 8, 2018
Mar. 9, 2018	Added coverage for CyPass and XEN45 devices

Applicable Procedure Codes

0191T	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, internal approach, into the trabecular meshwork; initial insertion (del. 01/01/2022)
0449T	Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; initial device

0671T	Insertion of anterior segment aqueous drainage device into the trabecular meshwork, without external reservoir, and without concomitant cataract removal, one or more (eff. 01/01/2022)
65855	Trabeculectomy by laser surgery
66150	Fistulization of sclera for glaucoma; trephination with iridectomy
66155	Fistulization of sclera for glaucoma; thermocauterization with iridectomy
66160	Fistulization of sclera for glaucoma; sclerectomy with punch or scissors, with iridectomy
66180	Aqueous shunt to extraocular equatorial plate reservoir, external approach; with graft
66183	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external approach
66184	Revision of aqueous shunt to extraocular equatorial plate reservoir; without graft
66185	Revision of aqueous shunt to extraocular equatorial plate reservoir; with graft
66710	Ciliary body destruction; cyclophotocoagulation, transscleral
66720	Ciliary body destruction; cryotherapy
66761	Iridotomy/iridectomy by laser surgery (eg, for glaucoma) (per session)
66989	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage; with insertion of intraocular (eg, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more (effective 01/01/2022)
66991	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); with insertion of intraocular (eg, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more (effective 01/01/2022)
J0171	Injection, Adrenalin, epinephrine, 0.1 mg
J1120	Injection, acetazolamide sodium, up to 500 mg
J7315	Mitomycin, ophthalmic, 0.2 mg
L8612	Aqueous shunt

Applicable ICD-10 Codes

H25.10	Age-related nuclear cataract, unspecified eye
H25.11	Age-related nuclear cataract, right eye
H25.12	Age-related nuclear cataract, left eye
H25.13	Age-related nuclear cataract, bilateral
H25.20	Age-related cataract, morgagnian type, unspecified eye
H25.21	Age-related cataract, morgagnian type, right eye
H25.22	Age-related cataract, morgagnian type, left eye
H25.23	Age-related cataract, morgagnian type, bilateral
H25.811	Combined forms of age-related cataract, right eye
H25.812	Combined forms of age-related cataract, left eye
H25.813	Combined forms of age-related cataract, bilateral
H25.819	Combined forms of age-related cataract, unspecified eye
H25.89	Other age-related cataract

H25.9	Unspecified age-related cataract
H26.001	Unspecified infantile and juvenile cataract, right eye
H26.002	Unspecified infantile and juvenile cataract, left eye
H26.003	Unspecified infantile and juvenile cataract, bilateral
H26.009	Unspecified infantile and juvenile cataract, unspecified eye
H26.011	Infantile and juvenile cortical, lamellar, or zonular cataract, right eye
H26.012	Infantile and juvenile cortical, lamellar, or zonular cataract, left eye
H26.013	Infantile and juvenile cortical, lamellar, or zonular cataract, bilateral
H26.019	Infantile and juvenile cortical, lamellar, or zonular cataract, unspecified eye
H26.031	Infantile and juvenile nuclear cataract, right eye
H26.032	Infantile and juvenile nuclear cataract, left eye
H26.033	Infantile and juvenile nuclear cataract, bilateral
H26.039	Infantile and juvenile nuclear cataract, unspecified eye
H26.041	Anterior subcapsular polar infantile and juvenile cataract, right eye
H26.042	Anterior subcapsular polar infantile and juvenile cataract, left eye
H26.043	Anterior subcapsular polar infantile and juvenile cataract, bilateral
H26.049	Anterior subcapsular polar infantile and juvenile cataract, unspecified eye
H26.051	Posterior subcapsular polar infantile and juvenile cataract, right eye
H26.052	Posterior subcapsular polar infantile and juvenile cataract, left eye
H26.053	Posterior subcapsular polar infantile and juvenile cataract, bilateral
H26.059	Posterior subcapsular polar infantile and juvenile cataract, unspecified eye
H26.061	Combined forms of infantile and juvenile cataract, right eye
H26.062	Combined forms of infantile and juvenile cataract, left eye
H26.063	Combined forms of infantile and juvenile cataract, bilateral
H26.069	Combined forms of infantile and juvenile cataract, unspecified eye
H26.09	Other infantile and juvenile cataract
H26.101	Unspecified traumatic cataract, right eye
H26.102	Unspecified traumatic cataract, left eye
H26.103	Unspecified traumatic cataract, bilateral
H26.109	Unspecified traumatic cataract, unspecified eye
H26.111	Localized traumatic opacities, right eye
H26.112	Localized traumatic opacities, left eye
H26.113	Localized traumatic opacities, bilateral
H26.119	Localized traumatic opacities, unspecified eye
H26.121	Partially resolved traumatic cataract, right eye
H26.122	Partially resolved traumatic cataract, left eye
H26.123	Partially resolved traumatic cataract, bilateral
H26.129	Partially resolved traumatic cataract, unspecified eye
H26.131	Total traumatic cataract, right eye
H26.132	Total traumatic cataract, left eye

H26.133	Total traumatic cataract, bilateral
H26.139	Total traumatic cataract, unspecified eye
H26.20	Unspecified complicated cataract
H26.211	Cataract with neovascularization, right eye
H26.212	Cataract with neovascularization, left eye
H26.213	Cataract with neovascularization, bilateral
H26.219	Cataract with neovascularization, unspecified eye
H26.221	Cataract secondary to ocular disorders (degenerative) (inflammatory), right eye
H26.222	Cataract secondary to ocular disorders (degenerative) (inflammatory), left eye
H26.223	Cataract secondary to ocular disorders (degenerative) (inflammatory), bilateral
H26.229	Cataract secondary to ocular disorders (degenerative) (inflammatory), unspecified eye
H26.231	Glaucomatous flecks (subcapsular), right eye
H26.232	Glaucomatous flecks (subcapsular), left eye
H26.233	Glaucomatous flecks (subcapsular), bilateral
H26.239	Glaucomatous flecks (subcapsular), unspecified eye
H26.30	Drug-induced cataract, unspecified eye
H26.31	Drug-induced cataract, right eye
H26.32	Drug-induced cataract, left eye
H26.33	Drug-induced cataract, bilateral
H26.40	Unspecified secondary cataract
H26.411	Soemmering's ring, right eye
H26.412	Soemmering's ring, left eye
H26.413	Soemmering's ring, bilateral
H26.419	Soemmering's ring, unspecified eye
H26.491	Other secondary cataract, right eye
H26.492	Other secondary cataract, left eye
H26.493	Other secondary cataract, bilateral
H26.499	Other secondary cataract, unspecified eye
H26.8	Other specified cataract
H26.9	Unspecified cataract
H40.012	Open angle with borderline findings, low risk, left eye
H40.013	Open angle with borderline findings, low risk, bilateral
H40.019	Open angle with borderline findings, low risk, unspecified eye
H40.021	Open angle with borderline findings, high risk, right eye
H40.022	Open angle with borderline findings, high risk, left eye
H40.023	Open angle with borderline findings, high risk, bilateral
H40.029	Open angle with borderline findings, high risk, unspecified eye
H40.031	Anatomical narrow angle, right eye
H40.032	Anatomical narrow angle, left eye
H40.033	Anatomical narrow angle, bilateral

H40.051	Ocular hypertension, right eye
H40.052	Ocular hypertension, left eye
H40.053	Ocular hypertension, bilateral
H40.059	Ocular hypertension, unspecified eye
H40.10X1	Unspecified open-angle glaucoma, mild stage
H40.10X2	Unspecified open-angle glaucoma, moderate stage
H40.1111	Primary open-angle glaucoma, right eye, mild stage
H40.1112	Primary open-angle glaucoma, right eye, moderate stage
H40.1113	Primary open-angle glaucoma, right eye, severe stage
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage
H40.1121	Primary open-angle glaucoma, left eye, mild stage
H40.1122	Primary open-angle glaucoma, left eye, moderate stage
H40.1123	Primary open-angle glaucoma, left eye, severe stage
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage
H40.1131	Primary open-angle glaucoma, bilateral, mild stage
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage
H40.1133	Primary open-angle glaucoma, bilateral, severe stage
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage
H40.1211	Low-tension glaucoma, right eye, mild stage
H40.1212	Low-tension glaucoma, right eye, moderate stage
H40.1213	Low-tension glaucoma, right eye, severe stage
H40.1214	Low-tension glaucoma, right eye, indeterminate stage
H40.1221	Low-tension glaucoma, left eye, mild stage
H40.1222	Low-tension glaucoma, left eye, moderate stage
H40.1223	Low-tension glaucoma, right eye, severe stage
H40.1224	Low-tension glaucoma, left eye, indeterminate stage
H40.1231	Low-tension glaucoma, bilateral, mild stage
H40.1232	Low-tension glaucoma, bilateral, moderate stage
H40.1233	Low-tension glaucoma, bilateral, severe stage
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage
H40.1311	Pigmentary glaucoma, right eye, mild stage
H40.1312	Pigmentary glaucoma, right eye, moderate stage
H40.1313	Pigmentary glaucoma, right eye, severe stage
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage
H40.1321	Pigmentary glaucoma, left eye, mild stage
H40.1322	Pigmentary glaucoma, left eye, moderate stage
H40.1323	Pigmentary glaucoma, left eye, severe stage
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage

H40.1331	Pigmentary glaucoma, left eye, mild stage
H40.1332	Pigmentary glaucoma, bilateral, moderate stage
H40.1333	Pigmentary glaucoma, bilateral, severe stage
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage
H40.89	Other specified glaucoma
Q12.0	Congenital cataract

References

1. Academy of Ophthalmology. Ophthalmology. 2011;118(7):1466-1480.
2. AHRQ. Treatment for Glaucoma Effectiveness. Comparative Effectiveness Review. Publication No. 12-EHC038. April 2012. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/glaucoma-treatment_research.pdf. Accessed January 20, 2022.
3. American Academy of Ophthalmology (AAO), Glaucoma Panel, Preferred Practice Patterns Committee. Primary open-angle glaucoma. Preferred Practice Pattern. San Francisco, CA: AAO; 2010.
4. American Academy of Ophthalmology (AAO). Primary Open angle glaucoma. Preferred Practice Pattern. Revised November 2015. <http://www.aaojournal.org/article/S0161-6420%2815%2901271-3/fulltext>. Accessed January 20, 2022.
5. American Optometric Association. Care of the patient with open angle glaucoma. 2nd ed. St. Louis, MO: American Optometric Association; August 17, 2002 (reviewed 2007).
6. Arriola-Villalobos P, Martinez-de-la-Casa JM, Diaz-Valle D, et al. Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: A long-term study. Br J Ophthalmol. 2012;96(5):645-649.
7. Augustinus CJ, Zeyen T. The effect of phacoemulsification and combined phaco/glaucoma procedures on the intraocular pressure in open-angle glaucoma. A review of the literature. Bull Soc Belge Ophtalmol. 2012;(320):51-66.
8. Aung T, Seah SK. Glaucoma drainage implants in Asian eyes. Ophthalmology. 1998;105 (11):2117-2122.
9. Ayyala RS, Zurakowski D, Monshizadeh R, et al. Comparison of double-plate Molteno and Ahmed glaucoma valve in patients with advanced uncontrolled glaucoma. Ophthalmic Surg Lasers. 2002;33(2):94-101.

10. Ayyala RS, Zurakowski D, Smith JA, et al. A clinical study of the Ahmed Glaucoma Valve implant in advanced glaucoma. *Ophthalmology*. 1998;105(10):1968-1976.
11. Barton K, Gedde SJ, Budenz DL, et al; Ahmed Baerveldt Comparison Study Group. The Ahmed Baerveldt Comparison Study methodology, baseline patient characteristics, and intraoperative complications. *Ophthalmology*. 2011;118(3):435-442.
12. Bissig A, Feusier M, Mermoud A, Roy S. Deep sclerectomy with the Ex-PRESS X-200 implant for the surgical treatment of glaucoma. *Int Ophthalmol*. 2010;30(6):661-668.
13. Boland MV, Ervin AM, Friedman D, et al. Treatment for glaucoma: Comparative effectiveness. Comparative Effectiveness Review No. 60. Prepared by the Johns Hopkins University Evidence-based Practice Center for the Agency for Healthcare Research and Quality (AHRQ) under Contract No. HHS 290-2007-10061-I.
14. Bryant J. Laser trabeculoplasty as primary therapy for glaucoma. DEC Report No. 62. Southampton, UK: Wessex Institute for Health Research and Development (WIHRD); 1996. Englert JA, Freedman SF, Cox TA. The Ahmed valve in refractory pediatric glaucoma. *Am J Ophthalmol*. 1999;127(1):34-42.
15. Buchacra O, Duch S, Milla E, Stirbu O. One-year analysis of the iStent trabecular microbypass in secondary glaucoma. *Clin Ophthalmol*. 2011;5:321-326.
16. Burr J, Azuara-Blanco A, Avenell A, Tuulonen A. Medical versus surgical interventions for open angle glaucoma. *Cochrane Database Syst Rev*. 2012;9:CD004399.
17. Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open angle glaucoma. *Cochrane Database Syst Rev*. 2004;(2):CD004399.
18. Cantor L, Burgoyne J, Sanders S, et al. The effect of mitomycin C on Molteno implant surgery: A 1-year randomized, masked, prospective study. *J Glaucoma* 1998;7:240-246.
19. Ceballos EM, Parrish RK 2nd, Schiffman JC. Outcome of Baerveldt glaucoma drainage implants for the treatment of uveitic glaucoma. *Ophthalmology*. 2002;109(12):2256-2260.
20. Chen G, Li W, Jiang F, et al. Ex-PRESS implantation versus trabeculectomy in open-angle glaucoma: A meta-analysis of randomized controlled clinical trials. *PLoS One*. 2014;9(1):e86045.
21. Cheng JW, Wei RL, Cai JP, Li Y. Efficacy and tolerability of nonpenetrating filtering surgery with and without implant in treatment of open angle glaucoma: A quantitative evaluation of the evidence. *J Glaucoma*. 2009;18(3):233-237.
22. Christakis PG, Tsai JC, Kalenak JW, et al. The Ahmed versus Baerveldt study: Three-year treatment outcomes. *Ophthalmology*. 2013;120(11):2232-2240.
23. Costa VP, Azuara-Blanco A, Netland PA, et al. Efficacy and safety of adjunctive mitomycin C during Ahmed glaucoma valve implantation: A prospective randomized clinical trial. *Ophthalmology* 2004;111:1071-1076.
24. Coupin A, Li Q, Riss I. [Ex-PRESS miniature glaucoma implant inserted under a scleral flap in open-angle glaucoma surgery: A retrospective study]. *J Fr Ophtalmol*. 200730(1):18-23.
25. Craven ER, Katz LJ, Wells JM, Giamporcaro JE; iStent Study Group. Cataract surgery with trabecular microbypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: Two-year follow-up. *J Cataract Refract Surg*. 2012;38(8):1339-1345. Food and Drug Administration. FDA approves first glaucoma stent for use with cataract surgery. June 25, 2012. FDA: Silver Spring, MD. <https://www.ncbi.nlm.nih.gov/pubmed/22814041>. Accessed January 20, 2022.
26. Dahan E, Ben Simon GJ, Lafuma A. Comparison of trabeculectomy and Ex-PRESS implantation in fellow eyes of the same patient: A prospective, randomised study. *Eye (Lond)*. 2012;26(5):703-710.
27. de Jong L, Lafuma A, Aguadé AS, Berdeaux G. Five-year extension of a clinical trial comparing the EX-PRESS

- glaucoma filtration device and trabeculectomy in primary open-angle glaucoma. *Clin Ophthalmol.* 2011;5:527- 533.
28. de Jong LA. The Ex-PRESS glaucoma shunt versus trabeculectomy in open-angle glaucoma: A prospective randomized study. *Adv Ther.* 2009;26(3):336-345.
 29. Doi LM, Melo LA Jr, Prata JA Jr. Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: A randomised clinical trial. *Br J Ophthalmol.* 2005;89(5):547-549.
 30. Duan X, Jiang Y, Qing G. Long-term follow-up study on Hunan aqueous drainage implantation combined with mitomycin C for refractory glaucoma [in Chinese]. *Yan Ke Xue Bao* 2003;19:81–85.

31. Eldaly MA, Bunce C, Elsheitka OZ, Wormald R. Non-penetrating filtration surgery versus trabeculectomy for open-angle glaucoma. *Cochrane Database Syst Rev.* 2014;2:CD007059.
32. Francis BA, Singh K, Lin SC, et al. Novel glaucoma procedures: A report by the American Academy of Ophthalmology. *Ophthalmology.* 2011;118(7):1466-1480.
33. Francis BA, Winarko J. Ab interno Schlemm's canal surgery: Trabectome and i-stent. *Dev Ophthalmol.* 2012;50:125-136.
34. Fuller JR, Bevin TH, Molteno AC. Long-term follow-up of traumatic glaucoma treated with Molteno implants. *Ophthalmology.* 2001;108(10):1796-1800.
35. Green E, Wilkins M, Bunce C, Wormald R. 5-Fluorouracil for glaucoma surgery. *Cochrane Database Syst Rev.* 2014;2:CD001132.
36. Grover DS, Godfrey DG, Smith O, et al. Gonioscopy-assisted transluminal trabeculectomy, ab interno trabeculectomy: Technique report and preliminary results. *Ophthalmology.* 2014;121(4):855-861.
37. Guttman C. Transciliary filtration provides improved safety and simplicity. *Ophthalmology Times.* February 1, 2005. Available at: <http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=145567>. Accessed November 11, 2005.
38. Hong CH, Arosemena A, Zurakowski D, Ayyala RS. Glaucoma drainage devices: A systematic literature review and current controversies. *Surv Ophthalmol.* 2005;50(1):48-60.
39. Huang MC, Netland PA, Coleman AL, et al. Intermediate-term clinical experience with the Ahmed Glaucoma Valve implant. *Am J Ophthalmol.* 1999;127(1):27-33.
40. Ishida K, Mandal AK, Netland PA. Glaucoma drainage implants in pediatric patients. *Ophthalmol Clin North Am.* 2005;18(3):431-442, vii.
41. Jea SY, Francis BA, Vakili G, et al. Ab interno trabeculectomy versus trabeculectomy for open-angle glaucoma. *Ophthalmology.* 2012;119(1):36-42.
42. Jordan JF, Engels BF, Dinslage S, et al. A novel approach to suprachoroidal drainage for the surgical treatment of intractable glaucoma. *J Glaucoma.* 2006;15(3):200-205.
43. Ke M, Guo J, Qian Z. Meta analysis of non-penetrating trabecular surgery versus trabeculectomy for the treatment of open angle glaucoma. *J Huazhong Univ Sci Technolog Med Sci.* 2011;31(2):264-270.
44. Kim DM, Lim KH. Aqueous shunts: Single-plate Molteno vs ACTSEB. *Acta Ophthalmol Scand.* 1995;73(3):277-280.
45. Kirwan JF, Rennie C, Evans JR. Beta radiation for glaucoma surgery. *Cochrane Database Syst Rev.* 2009;(2):CD003433.
46. Krishna R, Godfrey DG, Budenz DL, et al. Intermediate-term outcomes of 350-mm(2) Baerveldt glaucoma implants. *Ophthalmology.* 2001;108(3):621-626.
47. Mansouri K, Tran HV, Ravinet E, Mermoud A. Comparing deep sclerectomy with collagen implant to the new method of very deep sclerectomy with collagen implant: A single-masked randomized controlled trial. *J Glaucoma.* 2010;19(1):24-30.
48. Maris PJ Jr, Ishida K, Netland PA. Comparison of trabeculectomy with Ex-PRESS miniature glaucoma device implanted under scleral flap. *J Glaucoma.* 2007;16(1):14-19.
49. Maris PJ Jr, Ishida K, Netland PA. Comparison of trabeculectomy with Ex-PRESS miniature glaucoma device implanted under scleral flap. *J Glaucoma.* 2007;16(1):14-19.
50. Melamed S, Fiore PM. Molteno implant surgery in refractory glaucoma. *Surv Ophthalmol.* 1990;34(6):441-448.

51. Minckler DS, Francis BA, Hodapp EA, et al. Aqueous shunts in glaucoma: A report by the American Academy of Ophthalmology. *Ophthalmology*. 2008;115(6):1089-1098.
52. Minckler DS, Francis BA, Hodapp EA, et al. Aqueous shunts in glaucoma: A report by the American Academy of Ophthalmology. *Ophthalmology*. 2008;115(6):1089-1098. Filippopoulos T, Rhee DJ. Novel surgical procedures in glaucoma: Advances in penetrating glaucoma surgery. *Curr Opin Ophthalmol*. 2008;19(2):149-154.
53. Minckler DS, Hill RA. Use of novel devices for control of intraocular pressure. *Exp Eye Res*. 2009;88(4):792-798.
54. Minckler DS, Vedula SS, Li TJ, et al. Aqueous shunts for glaucoma. *Cochrane Database Sys Rev*. 2006;(2):CD004918.
55. Nassiri N, Kamali G, Rahnavardi M, et al. Ahmed glaucoma valve and single-plate Molteno implants in treatment of refractory glaucoma: A comparative study. *Am J Ophthalmol*. 2010;149 (6):893-902.
56. National Government Services. Local Coverage Determination (LCD): Micro-Invasive Glaucoma Surgery (MIGS). December 2019. https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37244&ver=28&CntrctrSelected=274*1&Cntrctr=274&name=&DocType=All&LCntrctr=274*1&bc=AgACAAQBAAA&. Accessed January 20, 2022.
57. Ng WS, Ang GS, Azuara-Blanco A. Laser peripheral iridoplasty for angle-closure. *Cochrane Database Syst Rev*. 2012;(2):CD006746.
58. Price FW Jr., Wellemeier M. Long-term results of Molteno implants. *Ophthalmic Surg*. 1995;26 (2):130-135.
59. Radcliffe NM, Musch DC, Niziol LM, et al; Collaborative Initial Glaucoma Treatment Study Group. The effect of trabeculectomy on intraocular pressure of the untreated fellow eye in the collaborative initial glaucoma treatment study. *Ophthalmology*. 2010;117(11):2055-2060.
60. Rivier D, Roy S, Mermoud A. Ex-PRESS R-50 miniature glaucoma implant insertion under the conjunctiva combined with cataract extraction. *J Cataract Refract Surg*. 2007;33(11):1946-1952. Ayyala RS, Hong C. Glaucoma, drainage devices. *eMedicine Ophthalmology Topic 754*. Omaha, NE: eMedicine.com; updated October 31, 2005.
61. Saheb H, Ahmed II. Micro-invasive glaucoma surgery: Current perspectives and future directions. *Curr Opin Ophthalmol*. 2012;23(2):96-104.
62. Samples JR, Singh K, Lin SC, et al. Laser trabeculoplasty for open-angle glaucoma: A report by the American Academy of Ophthalmology. *Ophthalmology*. 2011;118(11):2296-2302.
63. Sarkisian SR Jr. Use of an injector for the Ex-PRESS Mini Glaucoma Shunt. *Ophthalmic Surg Lasers Imaging*. 2007;38(5):434-436.
64. Schwartz KS, Lee RK, Gedde SJ. Glaucoma drainage implants: A critical comparison of types. *Curr Opin Ophthalmol*. 2006;17(2):181-189.
65. Singapore Ministry of Health. Glaucoma. Guidelines. Singapore: Singapore Ministry of Health; October 2005.
66. Singh D, Singh, K. Transciliary filtration using the fugo blade. *Ann Ophthalmol*. 2002;34(3):183-187.
67. Singh D, Verma A, Singh M. Transciliary filtration for intractable glaucoma. *Trans Ophthalmol. Soc U K*. 1979;99(1):92-95.
68. Smith MF, Doyle JW, Fanous MM. Modified aqueous drainage implants in the treatment of complicated glaucomas in eyes with pre-existing episcleral bands. *Ophthalmology*. 1998;105 (12):2237-2242.
69. Smith MF, Doyle JW, Sherwood MB. Comparison of the Baerveldt glaucoma implant with the double-plate Molteno drainage implant. *Arch Ophthalmol*. 1995;113(4):444-447.
70. Specialty matched clinical peer review.

71. Spiegel D, Kobuch K. Trabecular meshwork bypass tube shunt: Initial case series. *Br J Ophthalmol*. 2002;86(11):1228-1231.
72. Spiegel D, Wetzel W, Haffner DS, et al. Initial clinical experience with the trabecular micro- bypass stent in patients with glaucoma. *Adv Ther*. 2007; 24(1):161-170.
73. Stein JD, Challa P. Mechanisms of action and efficacy of argon laser trabeculoplasty and selective laser trabeculoplasty. *Curr Opin Ophthalmol*. 2007;18(2):140-145.
74. Stein JD, Herndon LW, Brent Bond J, et al. Exposure of Ex-PRESS miniature glaucoma devices: Case series and technique for tube shunt removal. *J Glaucoma*. 2007;16(8):704-706.
75. Thomas R, Gieser SC, Billson F. Molteno implant surgery for advanced glaucoma. *Aust N Z J Ophthalmol*. 1995;23(1):9-15.
76. Tice J. Aqueous shunts for the treatment of glaucoma. *Technology Assessment*. San Francisco, CA: California Technology Assessment Forum (CTAF); June 29, 2011.
77. Topouzis F, Coleman AL, Choplin N, et al. Follow-up of the original cohort with the Ahmed glaucoma valve implant. *Am J Ophthalmol*. 1999;128(2):198-204.
78. Uva MG, Longo A, Reibaldi M. Pneumatic trabeculoplasty versus argon laser trabeculoplasty in primary open- angle glaucoma. *Ophthalmologica*. 2010;224(1):10-15.
79. Valimaki J, Tuulonen A, Airaksinen PJ. Outcome of Molteno implantation surgery in refractory glaucoma and the effect of total and partial tube ligation on the success rate. *Acta Ophthalmol Scand*. 1998;76(2):213-219.
80. Wang H, Cheng JW, Wei RL, et al. Meta-analysis of selective laser trabeculoplasty with argon laser trabeculoplasty in the treatment of open-angle glaucoma. *Can J Ophthalmol*. 2013;48(3):186-192.
81. White TC. Aqueous shunt implant surgery for refractory glaucoma. *J Ophthalmic Nurs Technol*. 1996;15(1):7-13.
82. Wilson RP, Cantor L, Katz LJ, et al. Aqueous shunts. Molteno versus Schocket. *Ophthalmology*. 1992;99(5):672- 676; discussion 676-678.
83. Zhou J, Smedley GT. A trabecular bypass flow hypothesis. *J Glaucoma*. 2005;14(1):74-83.
84. Zhou J, Smedley GT. Trabecular bypass: Effect of schlemm canal and collector channel dilation. *J Glaucoma*. 2006; 15(5):446-455.
85. U.S. Food & Drug Administration. Hydrus® Microstent — P170034. September 2019. https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm620440.htm?utm_campaign=Recently%20Approved%20Devices&utm_medium=email&utm_source=Eloqua&elqTrackId=708D50160915A726A00765F2B7C00EE3&elq=e3267e4e1fe3401c964c28d4645_2968c&elqaid=5071&elqat=1&elqCampaignId=4044. January 20, 2022.
86. U.S. Food & Drug Administration. Potential Eye Damage From Alcon CyPass Micro-Stent Used to Treat Open-Angle Glaucoma: FDA Safety Communication. Sept. 2018. <https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm620646.htm>. Accessed January 20, 2022.